Colitis Home > Natalizumab
Clinical EffectsNatalizumab has been shown to prevent relapse (flare-ups) and slow down the progression of disability in people with MS. In a clinical study, 67 percent of people given natalizumab for two years had no flare-ups, compared to 41 percent of people given a placebo (a "sugar pill" that does not contain any active ingredients). Also, 83 percent of people on natalizumab did not have worsening disability over the two years, compared to 71 percent of those taking a placebo.
In clinical studies involving people with Crohn's disease, natalizumab was shown to decrease the occurrence of symptoms. In one study, 60 percent of people given natalizumab had a significant decrease in symptoms after 12 weeks of treatment, and 37 percent of people were in remission (little or no symptoms). In comparison, 44 percent of those given a placebo responded to treatment, and 25 percent experienced remission at week 12.
When and How to Receive This MedicineSome general considerations to keep in mind during treatment with natalizumab include the following:
- This medication is given as a slow injection into a vein (an intravenous, or IV, infusion). It is usually given once every four weeks.
- The injections are given by a healthcare provider in a healthcare setting.
- It will take about one hour to give each dose of natalizumab. You will also need to be observed for at least one hour after the dose is given, to make sure you don't experience allergic reactions to the medication.
- Natalizumab solution must be diluted prior to use. The solution should not be used if the medication is discolored, cloudy, or contains particles.
- You can only receive this medication if you, your healthcare provider, and the place you receive your injection are enrolled in a special program called the Touch® program.
- For this drug to work properly, it must be used as prescribed. The medication will not work as well if you miss doses.